Group 1 - The article discusses the investment opportunities in ImmunityBio, Inc. (NASDAQ: IBRX), highlighting previous coverage and ratings issued by the author, including a "Hold" rating since April last year [1] - The Haggerston BioHealth marketplace channel offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to financial models and research [1] - The investing group is designed for both novice and experienced biotech investors, offering insights on catalysts, product sales forecasts, and integrated financial statements [1] Group 2 - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, with detailed reports on over 1,000 companies [1]

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 240 patents [1][5] - The company presented research on a scalable artificial thymus organoid at the ThymUS 2025 Meeting, which aims to recover the functionality of the thymus [2][3] Company Overview - Founded in 2001, FibroBiologics is based in Houston and is engaged in developing a pipeline of treatments for various chronic diseases, including multiple sclerosis, cancer, and wound healing [5] - The company emphasizes the unique immunomodulatory properties of fibroblasts, which are believed to enhance the functionality and durability of therapeutic organoids [3][5] Research and Development - The presented abstract details a method for developing transplantable and scalable thymus organoids that can generate functional T cells, indicating significant progress in the field [2][3] - The research highlights the potential of organoids to transform the study and treatment of chronic diseases, showcasing the innovative approaches being explored by the company [3]

This news release contains forward-looking statements relating to, among other things, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations ...

Core Points - INOVIO, a biotechnology company, focuses on developing and commercializing DNA medicines for HPV-associated diseases, cancers, and infectious diseases [1][3] - The company will release its first quarter 2025 financial results on May 13, 2025, after market close [1] - A live conference call and webcast will follow the financial results release at 4:30 p.m. ET, including a Q&A session with analysts [1][2] Company Overview - INOVIO's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [3] - The company aims to protect and treat individuals from HPV-related diseases and other infectious diseases through its innovative approach [3]

Core Viewpoint - BioAtla, Inc. is set to host a conference call on May 6, 2025, to discuss its Q1 2025 financial results and business highlights [1][2]. Company Overview - BioAtla is a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [3]. - The company operates in San Diego, California, and Beijing, China, through a partnership with BioDuro-Sundia for preclinical development services [3]. - BioAtla utilizes its proprietary CAB platform technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3]. - The company holds extensive patent coverage with over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3]. Product Development - BioAtla's first dual CAB bispecific T-cell engager antibody, BA3182, is in Phase 1 development, targeting EpCAM, which is commonly expressed in adenocarcinomas [3]. - The company has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) [3]. - The Phase 2 CAB-CTLA-4 antibody, evalstotug, is designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors like anti-PD-1 antibody [3].

Core Insights - Pasithea Therapeutics Corp. has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004, a next-generation macrocyclic MEK inhibitor for treating neurofibromatosis type 1 (NF1) and other MAPK pathway driven cancers [1][2] Group 1: Clinical Trial Progress - The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with documented RAS, NF1, or RAF mutations, or patients who have failed BRAF/MEK inhibition [3] - The company expects to complete enrollment of all patients in the trial by the end of 2025, having recruited and commenced dosing of the initial three subjects more rapidly than anticipated [2] Group 2: Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, RASopathies, and MAPK pathway driven tumors [4]

Core Insights - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [1][3] - The company will participate in two upcoming investor events, including a fireside chat and a corporate overview presentation [1][4] Company Overview - Dianthus Therapeutics is dedicated to designing and delivering novel, best-in-class monoclonal antibodies with enhanced selectivity and potency [3] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [3] Upcoming Events - Marino Garcia, the Chief Executive Officer, will participate in a fireside chat webcast on May 6 at 1:30 p.m. EDT [4] - The CEO will also present a corporate overview at the Bank of America 2025 Health Care Conference on May 14 at 5:35 p.m. EDT and will conduct one-on-one meetings with investors [4]

ST. PAUL, Minn., April 29, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been awarded a $200,000 G-Rex® Grant. March Biosciences' G-Rex® Grant will be used to advance the manufacturing of their lead asset, MB-105, a novel investigational autologous CAR-T cell therapy targeting CD5 for patients with T-cell lymphomas. "As we ramp up clinical manufacturing and advance towards commercialization o ...

HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT. A live webcast of the fireside chat style presentation will be accessible to registered attendees via the following link: https://us02web.zoom. ...

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant timeframe have until May 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].